WORST OF BARRIER REVERSE CONVERTIBLE LINKED TO WORST OF - NOVARTIS N/BAYER/SIEMENS/ROCHE GS Share Price

Certificat

KOOGDU

CH1280820874

Delayed Swiss Exchange 09:50:00 09/01/2024 pm IST
88.4 CHF +1.43% Intraday chart for WORST OF BARRIER REVERSE CONVERTIBLE LINKED TO WORST OF - NOVARTIS N/BAYER/SIEMENS/ROCHE GS
1 month+13.84%
Current year+6.19%

Static data

Product typeReverse Convertibles
Buy / SellCALL
Underlying ROCHE HOLDING AG
Issuer UBS
KOOGDU
ISINCH1280820874
Date issued 19/07/2023
Strike 271.2 CHF
Maturity 19/07/2024 (61 Days)
Parity 1 : 1
Emission price 100 CHF
Emission volume N/A
Settlement cash
Currency CHF

Technical Indicators

Highest since issue 101 CHF
Lowest since issue 70.85 CHF

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
237.1 CHF
Average target price
279.4 CHF
Spread / Average Target
+17.84%
Consensus
  1. Stock Market
  2. Certificates
  3. KOOGDU Certificat
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW